Status:
COMPLETED
Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Duke University
GlaxoSmithKline
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Pa...
Detailed Description
We hope to learn whether ropinirole CR (controlled release formulation) is safe and effective when taken with an antidepressant to reduce the symptoms of depression. Adults who have a diagnosis of maj...
Eligibility Criteria
Inclusion
- Age 18 to 65 years old
- Currently experiencing major depression
- On at least an adequate dose of fluoxetine, paroxetine, sertraline, citalopram, escitalopram, venlafaxine, bupropion, mirtazapine or duloxetine for at least 6 weeks (monotherapy).
Exclusion
- Pregnant females or females of child bearing years not using adequate birth control in the opinion of the investigators
- Known sensitivity to ropinirole
- Significant medical conditions that would preclude safe participation in the study in the opinion of the investigators.
- Significant abnormalities observed in screening laboratory evaluation
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00285727
Start Date
January 1 2006
End Date
October 1 2007
Last Update
May 19 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305
2
Depression Research Clinic, Psychiatry Department, Stanford School of Medicine
Stanford, California, United States, 9430